Abagovomab

From WikiMD's WELLNESSPEDIA

Abagovomab is a monoclonal antibody used in the treatment of ovarian cancer

Abagovomab
Abagovomab

Other names[edit]

  • ACA 125
  • Anti-idiotype ovarian cancer vaccine
  • MAb ACA 125
  • Monoclonal Anti-idiotype Antibody ACA125

Indications[edit]

Abagovomab is studied as an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer

Mechanism of action[edit]

  • A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity.
  • With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation resulting in inhibition of tumor cell proliferation
Diagram showing stage 3A to 3C ovarian cancer
Diagram showing stage 3A to 3C ovarian cancer

Manufacturer[edit]

Abagovomab has been developed by the pharmaceutical company Menarini.

Clinical trials[edit]

A multicenter clinical trial, internationally known as MIMOSA is being studied. In this study, Abagovomab was administered as maintenance therapy after first line therapy with surgery and chemotherapy, as opposed to standard therapy with paclitaxel and carboplatin.

Ovarian cancer[edit]

Ovarian cancer is an aggressive type of cancer with significant mortality. In spite of initially successful treatment with surgery and chemotherapy, which forces back the tumour "completely", i.e. into no longer visible residues, there is a relapse of the disease (recurrence) in more than half the women affected. In this window, after surgery and chemotherapy, ‘watch and wait’ abagovomab is potentially capable of deferring or even preventing the occurrence of the relapse.

Also see[edit]

External links[edit]


Monoclonal antibodies for tumors
Tumor
Human
Mouse
Chimeric
Humanized
* Abituzumab§
Rat/mouse hybrid


Monoclonal antibodies for tumors
Tumor
Human
Mouse
Chimeric
Humanized
* Abituzumab§
Rat/mouse hybrid


Stub icon

This WikiMD article can only be edited by registered and verified editors. You can log in or register.

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Abagovomab&oldid=6618264"